Toggle Offcanvas
...
 
Ustekinumab Tenders

Ustekinumab Tenders

View Ustekinumab tenders, RFPs and contracts. Bid on readily available Ustekinumab tenders with the best and most comprehensive tendering platform, since 2002.

Bidding for Ustekinumab tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Ustekinumab.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Ustekinumab market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Ustekinumab tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

31 Live Notices for Ustekinumab Tenders

Showing 1 to 20

Specific Contract For The Supply Of Exclusive And/Or Infungable Drugs Through The Use Of The Sintel Platform, Pursuant To Art. 55, Paragraph 8 Of Legislative Decree 50/2016, As Part Of The Dynamic Acquisition System Called Aria2020305 "Dynamic Acquisition System For Supplies Of Pharmaceutical Products" - 2Nd Procedure Year 2025
country Italy
posting date13 Mar 2025
deadline27 Mar 2025
Medicinal Products Containing The Content Of Ustekinumab
country Czech Republic
posting date12 Mar 2025
deadline11 Apr 2025
Medicinal Products Containing The Content Of Ustekinumab
country Czech Republic
posting date05 Mar 2025
deadline04 Apr 2025
Supply Of Ustekinumab Ev 30 Fl By 130 Mg / 150 Sir Sc From 90 Mg / 25 Sir Sc From 45 Mg
country Italy
posting date04 Mar 2025
deadline12 Mar 2025
Request For Information: Equipment And Reagents For The Analysis Of Biological Drug Assays
country Finland
posting date26 Feb 2025
deadline01 May 2025
Pharmaceutical Discount Agreements Pursuant To Section 130A Paragraph 8 Of The Social Security Code (Sgb V) Within The Framework Of Open-House Procedures
country Germany
posting date31 Jan 2025
deadline06 May 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Security Code (Sgb) V For The Active Ingredient Ustekinumab, (Obg) Atc L04Ac05 For The Period 01.03.2025 - 28.02.2027
country Germany
posting date16 Jan 2025
deadline05 Jan 2027
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Security Code (Sgb) V For The Active Ingredient Ustekinumab, (Obg) Atc L04Ac05 For The Period 01.03.2025 - 28.02.2027
country Germany
posting date16 Jan 2025
deadline05 Jan 2027
Environmentally Friendly Supply Of Biological Human Medicines With Biosimilars For Public Health Centres In Valencia
country Spain
posting date30 Dec 2024
deadline01 Oct 2025
Pharmaceutical Discount Agreements From February 1, 2025 For Various Active Ingredients Within The Framework Of An Open-House Procedure
country Germany
posting date12 Dec 2024
deadline02 Dec 2026
Conclusion Of Non-Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8 Of The Social Security Code (Sgb) V For Medicinal Products (Open House Procedure)
country Germany
posting date30 Oct 2024
deadline20 Apr 2026
Medicines Containing The Active Substance Ustekinumab (Atc: L04Ac05)
country Germany
posting date22 Jun 2024
deadline31 May 2026
Conclusion Of A Non-Exclusive Discount Agreement According To Section 130A Paragraph 8 Sgb V For The Active Ingredient Ustekinumab, Atc L04Ac05 (Obo) For The Period 01.08.2024 - 31.07.2025 (Plus Extension Option 1X12 Months)
country Germany
posting date22 Jun 2024
deadline05 Jun 2026
Open House Drug Rebate Agreements Ustekinumab, Atc L04Ac05
country Germany
posting date22 Jun 2024
deadline05 Jun 2026
Open House Drug Rebate Agreements Ustekinumab, Atc L04Ac05
country Germany
posting date19 Jun 2024
deadline05 Jun 2026
Open House Drug Rebate Agreements Ustekinumab, Atc L04Ac05
country Germany
posting date19 Jun 2024
deadline05 Jun 2026
Open House Biologics Discount Agreements 2024-05 - Ustekinumab
country Germany
posting date17 Jun 2024
deadline31 Jul 2026
Open House Biologics Discount Agreements 2024-05 - Ustekinumab
country Germany
posting date17 Jun 2024
deadline31 Jul 2026
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For Medicinal Products Containing The Active Ingredient Ustekinumab (Atc Code: L04Ac05).
country Germany
posting date14 Jun 2024
deadline27 May 2026
Pharmaceutical Discount Agreements Pursuant To Section 130A Para. 8 Sgb V Within The Framework Of Open-House Procedures
country Germany
posting date14 Jun 2024
deadline06 May 2026

Share Share this page